EXHIBIT 99.1

   SciClone Announces Appointment of Richard J. Hawkins to Board of
                               Directors

    SAN MATEO, Calif.--(BUSINESS WIRE)--Nov. 1, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced the appointment of
Richard J. Hawkins to the company's Board of Directors as a
non-executive member.
    "Rick's experience in drug development, regulatory approval and
the leadership of rapidly growing pharmaceutical companies will
greatly contribute to SciClone's continued progress," commented Dr.
Jere E. Goyan, Chairman of SciClone Pharmaceuticals. "With his
comprehensive knowledge of the clinical development process as well as
his experience holding a number of key leadership positions, Rick will
bring valuable insight to SciClone as we work toward completion of our
ZADAXIN phase 3 hepatitis C clinical trials, advance the development
of SCV-07 and pegylated ZADAXIN, and pursue our plans to broaden our
product pipeline."
    Mr. Hawkins is a highly experienced executive with over 30 years
of experience in the pharmaceutical industry. Mr. Hawkins founded and
built Pharmaco to be a highly respected and leading clinical research
organization (CRO). In 1991 Pharmaco merged with the predecessor of
PPD-Pharmaco, becoming the cornerstone of one of the largest CROs in
the world today. Later, Mr. Hawkins went on to co-found and serve as
Chairman of Sensus Drug Development, which successfully developed and
received regulatory approval for SOMAVERT(R), a growth hormone
antagonist approved for the treatment of acromegaly. SOMAVERT is
marketed today by Pfizer in both the United States and Europe.
Currently, Mr. Hawkins serves as the Chairman and CEO of LabNow, Inc.,
a privately-held start-up company he founded. LabNow is developing
lab-on-a-chip sensor technology to be used in point-of-care, physician
office-based diagnostic testing systems. Mr. Hawkins graduated cum
laude with a Bachelors of Science in Biology from Ohio University in
1974.
    With Mr. Hawkin's appointment, SciClone's Board of Directors has
seven members, all of whom are independent, non-executive directors.

    About SciClone

    SciClone Pharmaceuticals is a biopharmaceutical company engaged in
the development of therapeutics to treat life-threatening diseases.
SciClone's lead product ZADAXIN(R) is currently being evaluated in two
phase 3 hepatitis C clinical trials in the United States. ZADAXIN is
also being evaluated in other late-stage clinical trials for the
treatment of hepatitis B and certain cancers. The company's other
principal drug development candidate is SCV-07, which is currently
being evaluated in pre-clinical studies for the treatment of viral and
other infectious disease. For more information about SciClone, visit
www.sciclone.com.

    CONTACT: SciClone Pharmaceuticals, Inc.
             Richard A. Waldron, 650-358-3437